Controversies and reappraisal in the management of distal deep vein thrombosis: From evidence-based discrepancies to risk-stratified individualized strategies

BackgroundDistal deep vein thrombosis (DVT) confined to the infrapopliteal deep venous system, commonly termed isolated distal deep vein thrombosis (IDDVT), accounts for a substantial proportion of lower-extremity DVT. Its optimal management remains controversial because randomized evidence is limited, patient populations are heterogeneous, and guideline recommendations differ.ObjectiveThis narrative review critically examines the evidence for anticoagulation and serial ultrasonographic surveillance in IDDVT, evaluates sources of uncertainty, compares major guideline recommendations, and proposes a cautious, risk-adapted framework for individualized management.MethodsWe searched PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library to identify English-language guidelines, randomized controlled trials, systematic reviews/meta-analyses, and relevant observational studies addressing IDDVT management, thrombus extension, pulmonary embolism, bleeding, post-thrombotic syndrome, and treatment duration. The search was updated through July 2026. Priority was given to major guidelines, randomized trials, and contemporary systematic reviews/meta-analyses, with older studies retained when providing foundational evidence.ResultsCurrent evidence does not support a uniform treatment strategy for IDDVT. The choice between anticoagulation and serial imaging should consider symptom severity, extension risk factors, bleeding risk, thrombus location, patient preferences, and feasibility of follow-up imaging. Randomized trials support surveillance in selected patients and suggest reduced recurrent VTE with extended anticoagulation in patients who tolerate initial treatment. However, evidence remains limited by small or selected populations, heterogeneous outcomes, and extrapolation from proximal DVT or pulmonary embolism.ConclusionIDDVT should be managed according to individual risk rather than as a homogeneous condition. Decisions regarding anticoagulation initiation and treatment duration should be considered separately. Serial imaging is reasonable for selected patients without severe symptoms or major extension risk factors, whereas anticoagulation is generally favored in those with severe symptoms or recognized extension risk factors. No IDDVT-specific risk score has been validated, and interventional treatment should remain exceptional because direct evidence is lacking.